Winter has come: focus on monitoring drug specification revision use again limited!

For key lying drugs, re-revising the instructions seems to be a trendthe instructionmanual is revised and the use of medicines is further restricted!in recent years, there have been occasional media reports of serious adverse reactions caused by the use of neurocone resin, a drugAlthough the State Drug Administration has previously issued the General Administration on the revision of single salivary acid quadricosaccharide sodium injection specification (No172), requiring all GM1 production enterprises at home and abroad to modify the product specification, add "Gillan-Barre syndrome" warningfor the compound injection of neurosyine lipid components, "brain glycoside carnosine injection" supervision, it seems not so strict, some media reports in the past period of time similar cases mentioned, some enterprises think that "the Drug Administration 172 document decided to "single salivary acid quadgother glycoside resin injection agent" specification to add warning words and revision, its target for the object of "single salivary quadricec acid glycosinosine glycosine this specific type of drug." "Brain gin carnosine injection" is a compound formulation, not within the scope of adjustmentthis time, the State Drug Administration in the brain glycoside carnosine injection revision instruction series announcement, in the brain glycodesinopeptide injection drug specification to add warning words, the focus includesthis product contains single salivary acid tetrahexygin nerve glycoside lipids." Cases of acute inflammatory demyelination multiple neuropathy (also known as Guillain-Barre syndrome) may be associated with the use of neurocone-syous lipid products were found in post-market monitoring at home and abroadIf the patient during the drug use (generally within 5-10 days after the drug) appears holding object sinability, limb weakness, flaccid paralysis and other symptoms, should immediately seek medical attentionPeople with Guillain-Barre syndrome are disabledaccording to the information in the, the content of neurocine lipids in cerebroside carnosine was 0.24 mg/mlRelevant people familiar with the matter said that the Drug Enforcement Administration to modify the drug specification, generally more than a certain variety of drugs, rarely targeted at a certain component of the drugAt present, the Drug Enforcement Administration this time alone modified the "brain gin carnosine injection" specification, is undoubtedly a direct blocking of some drug companies drilling loopholes, and further strengthen the focus of monitoring drug monitoringThis is not the first time thatrevised the specification for key lying drugsOn September 3, the State Drug Administration requested the "Dansanchuan yuan injection" to revise the specification, including the addition of warning words, adverse reactions, taboos, precautions to reviseIn 2018, the sales volume of the injections exceeded 4 billionassisted in the use of drugs to meet the "winter"According to the Insight database, the sales score for brain-side carnosine injections in 2017 was $3,267 million, compared with $2.2 billion in 2018Sina Pharma from the State Drug Administration's official website query learned that the current brain peptide injection manufacturers are mainly Jilin four ring pharmaceutical and Jilin Zhenao pharmaceuticalIt is worth noting that Jilin Four Rings is a wholly owned subsidiary of Beijing Four Rings, Jilin Zhenao is a wholly owned subsidiary of Jilin Four Rings, and Jilin Four Rings is the backbone member of the Four Rings Pharmaceutical Holdings Groupin the national version of the key monitoring drug catalog, a total of seven major products of four-ring medicine are included, including brain glycodesinopeptide injection, Malay acid cinnamon pyretit injection, quechidin brain protein hydrolysis injection, etc, these 7 products accounted for a total of 78.9% of the total sales of four-ring medicine in the first half of 2019According to Guotai Junan Securities Research Report analysis, the recent related policies will be in the short term to the four-ring medicine "cardiovascular portfolio" sales to bring some impact, will inevitably affect the company's operationsat the end of October, listed companies released three quarterly financial results, Sina Pharma observed Jingfeng Pharmaceuticals, Connbe, Lizhu Group and other found that these enterprises in the focus of monitoring the drug performance have declined to varying degreesThe fate of key monitoring drugs is obvious, and the performance of the four-ring medicine in the above-mentioned varieties is not optimisticthis winter can't be said to be winter for supplementary medicationAfter the use of limited medical insurance, the specification revision, the National Health and Reform Commission recently issued a more deadly blow, the National Health Reform Commission (2019) No2 requires the provinces by the end of December this year, the development of provincial key monitoring of rational drug products catalogue (chemical sand and biological products) and announced, by the end of December next year to fully establish a key drug monitoring mechanism ..Once the focus of monitoring drug catalog spread throughout the country, leaving the relevant enterprises to transform time is running outrelated reference articles:1 "God drug" neurotic sedation paraplegia survey: there are patients spending 1 million involved in step-by-step and other pharmaceutical companies 2 nervous system disease "over-use" survey: drug sales of more than 5 billion, side effects of paraplegia